Aquestive Therapeutics, Inc. Common Stock
$4.66
-$0.16 (-3.32%)
$4.62Day Range$5.00
Key Statistics
Market Cap
$604.97M
Shares Outstanding
125.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 25, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$5.00
Day High
$5.00
Day Low
$4.62
Volume
2.53M
VWAP
$4.73
Prev Close
$4.82
Transactions
--
Acc. Volume
--
About Aquestive Therapeutics, Inc. Common Stock
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
PHARMACEUTICAL PREPARATIONSSIC 2834147 employees30 TECHNOLOGY DRIVE, WARREN, NJ, 07059908-941-1900IPO Jul 25, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001398733
- Composite FIGI
- BBG00L9HP0Z0
- Share Class FIGI
- BBG00L9HP1R7
- Ticker Root
- AQST
- SIC Code
- 2834
About Aquestive Therapeutics, Inc. Common Stock (AQST) Stock
Aquestive Therapeutics, Inc. Common Stock (AQST) closed the 2026-09-17 session at $4.66, down 3.32% versus the previous close (-0.16). The stock opened at $5.00 and traded between $4.62 and $5.00 during that session. Session trading volume was 2.5M shares. The volume-weighted average price (VWAP) is $4.73.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics, Inc. Common Stock has a market capitalization of $605.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AQST is listed on the XNAS exchange. The company employs approximately 147 people. Aquestive Therapeutics, Inc. Common Stock is headquartered in WARREN, NJ. The recorded listing date is 2018-07-25.
On this page you can find market AQST stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.